MRI-Guided Radiotherapy Revolutionizes Prostate Cancer Treatment

A groundbreaking study by UCLA Health Jonsson Comprehensive Cancer Center reveals that MRI-guided stereotactic body radiotherapy (SBRT) dramatically decreases long-term side effects in prostate cancer treatment, particularly in bowel and sexual health, compared to conventional CT-guided approaches. The research, part of the phase 3 MIRAGE trial, aimed to assess the impact of MRI guidance on radiation therapy, offering a more precise treatment option that reduces exposure to healthy tissue. **Key findings** include a significant reduction in urinary and bowel side effects: only 27% of MRI-guided patients faced moderate or severe urinary issues, against 51% in the CT group. Gastrointestinal toxicity was also notably lower, with 1.4% vs. 9.5%, respectively. The results point to MRI guidance allowing more accurate targeting of the prostate with narrower planning margins, thereby reducing radiation exposure to nearby normal tissues. This technique contributes to enhanced patient quality of life, emphasizing the potential of MRI-guided SBRT to transform prostate cancer treatment protocols.